IRCT20170213032547N1已完成3 期
Effectiveness of Sofosbuvir/Daclatasvir for Treatment of People Who Inject Drug with HCV Infection in a Community-based Setting
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Being male or female (including transgender)
- •Being 18 years or older at the time of baseline interview
- •Self-reported drug injection with verification for non-medical purposes in the past twelve months
- •Having chronic infection of HCV as confirmed by HCV-RNA
- •Having lived for at least six months in Kerman and have no plan to move out for another three months
- •Having written informed consent to participate in the study
- •Understanding the Farsi language
排除标准
- •HBV/HCV Coinfection
- •Pregnant woman
- •TB/HCV Coinfection
- •eGFR<30 mL/min or chronic renal failure
- •Drug-drug interactions
研究者
相似试验
招募中
2 期
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infectionDRKS00022203PHARCO CORPORATE90
已完成
1 期
Efficacy of Daclatasvir+Sofosbuvir in patients with severe acute respiratory syndrome coronavirus (SARS-COVID-19)IRCT20200816048422N1Ahvaz University of Medical Sciences70
已完成
3 期
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000
已完成
3 期
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
招募中
2 期
Efficacy and safety of Sofosbuvir in the treatment of SARS-CoV-2: An Open Label phase II TrialSARS-CoV-2 ?associated SARI.SARS-CoV-2U07.1IRCT20200328046882N1Shahid Beheshti University of Medical Sciences60